Company Information
USD
3.59
- (3.5%)
NASDAQ:CVAC, CUREVAC N.V.
Industry: Biotechnology
End of Day: 8 May 2025 GMT-4
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Address
Friedrich-Miescher-Strasse 15
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Mr. Craig A. Tooman
Director
Mr. Baron Jean Stephenne
Chairman of the Board/Director
Mr. Klaus Schollmeier
Director
Dr. Mathias Hothum, PhD
Director
Dr. Debra Stephanie Barker
Director
Mr. Pierre Kemula
CFO
Dr. Igor Splawski, M.Sc.,PhD
Chief Scientific Officer
Mr. Ralf Clemens, M.D.,PhD
Director
Dr. Hans Christoph Tanner, PhD
Director
Ms. Viola Bronsema, PhD
Director
Dr. Antony Blanc, PhD
Other Executive Officer
Mr. Malte Greune, PhD
COO
Dr. Alexander Zehnder, M.B.A.,M.D.
CEO
Ms. Myriam Mendila
Other Executive Officer
Ownership
Institution Holdings
KFW
114,190,046 (50.995%)
GSK PLC
16,591,937 (7.410%)
Citadel Advisors Llc
3,073,993 (1.373%)
RA Capital Management, LLC
2,744,270 (1.226%)
RA Capital Management, LP
2,744,270 (1.226%)
Millennium Management LLC
2,728,903 (1.219%)
T. Rowe Price Associates, Inc.
2,324,274 (1.038%)
BlackRock Inc
1,805,596 (0.806%)
BlackRock Fund Advisors
1,788,215 (0.799%)
Camber Capital Management LLC
1,750,000 (0.782%)
Funds Holdings
US Small-Cap Growth II Equity Comp
1,837,611 (0.821%)
T. Rowe Price New Horizons Fund
1,837,611 (0.821%)
iShares Biotechnology ETF
702,774 (0.314%)
iShares Nasdaq US Biotechnology ETF
113,077 (0.051%)
State Street Gbl All Cap Equity ExUS NL
99,995 (0.045%)
BlackRock MSCI ACWI ex-U.S. IMI Index NL
86,503 (0.039%)
BlackRock MSCI ACWI ex-U.S. IMI Index
83,092 (0.037%)
Fidelity Nasdaq Composite Index ETF
73,036 (0.033%)
NT Dev Intl Small Cap Idx Fd - NL
70,904 (0.032%)
NT ACWI ex US IMI Fund - NL
61,411 (0.027%)
Make Smart Investment Choices
GoodWhale Pte. Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
